Lamivudine/nevirapine/zidovudine

Lamivudine/nevirapine/zidovudine
Combination of
Lamivudine	nucleoside reverse transcriptase inhibitor
Nevirapine	non-nucleoside reverse transcriptase inhibitor
Zidovudine	nucleoside reverse transcriptase inhibitor
Clinical data
Trade names	Duovir-N, Zidovex-LN, others
ATC code	J05AR05 (WHO) ;
Identifiers
CAS Number	1256374-17-0;
ChemSpider	none;

Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.^[2] It contains lamivudine, nevirapine, and zidovudine.^[2] It is either used by itself or along with other antiretrovirals.^[2] It is a recommended treatment in those who are pregnant.^[2] It is taken by mouth twice a day.^[2]

The medication is generally well tolerated.^[1] Side effects are those of the underlying medications.^[2] This includes rash, pancreatitis, low white blood cell levels, and muscle pain.^[1] Use is not recommended in those with significant liver problems.^[1] Use in pregnancy and breastfeeding appear to be safe.^[1] The combination tablet is typically not appropriate for children.^[2]

It is on the World Health Organization's List of Essential Medicines.^[3] The combination is not commercially available in the United States as of 2018.^[4]

References

^ ^a ^b ^c ^d ^e "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
^ ^a ^b ^c ^d ^e ^f ^g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.

Zdroj:https://en.wikipedia.org?pojem=Lamivudine/nevirapine/zidovudine
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[AIDS2016-1] "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.

[WHO2008-2] ^ ^a ^b ^c ^d ^e ^f ^g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.

[WHO21st-3] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[4] "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.

[1]

[2]

[3]

[4]

See also

References